Key Takeaways
- Wave Life Sciences shares plummeted 30% Thursday following the release of interim Phase 1 results from its INLIGHT obesity trial
- WVE-007 delivered a 14% placebo-adjusted visceral fat reduction with a single 240mg dose over a six-month period
- Study participants exhibited an average BMI of 32, significantly lower than the standard 37+ seen in most obesity clinical trials
- Jefferies sustained its Buy rating with a $28 price target on WVE prior to the data disclosure
- The company intends to launch Phase 2a of INLIGHT during Q2 2026, focusing on patients with elevated BMI and comorbidities
Wave Life Sciences unveiled interim Phase 1 results from its INLIGHT study on Thursday, triggering a sharp sell-off despite the company’s optimistic characterization of the findings. Shares collapsed 30% during trading hours.
The trial evaluated WVE-007, an investigational obesity therapy. Participants receiving a single 240mg dose experienced a placebo-adjusted 14% decrease in visceral fat over six months. The study population had an average BMI of 32 kg/m².
Additional findings included a 16.5% enhancement in visceral fat-to-muscle ratio from baseline measurements. Lean muscle mass grew by 2.4%, waist measurements declined 3.3%, and overall body weight decreased 0.9% when adjusted for placebo.
Safety data showed WVE-007 demonstrated tolerability at doses up to 600mg. No participants withdrew from treatment, and serious adverse events were absent. Serum Activin E reductions persisted for at least seven months, indicating potential for semi-annual or annual dosing schedules.
However, the trial’s patient population posed interpretation challenges. With a mean BMI of 32, participants were substantially leaner than the BMI 37+ populations commonly enrolled in later-stage obesity studies. This demographic difference complicates direct efficacy comparisons with competing therapies.
Wave drew comparisons between WVE-007’s visceral fat outcomes and weekly semaglutide data from an independent Phase 2 trial. Since that semaglutide study included higher-BMI participants, analysts questioned the validity of such cross-trial comparisons.
Market participants appeared skeptical, particularly given the intense competition in obesity therapeutics dominated by Novo Nordisk and Eli Lilly.
Next Phase on the Horizon
Wave intends to initiate the Phase 2a segment of INLIGHT during the second quarter of 2026. This expansion will recruit individuals with BMI ranging from 35 to 50 who also present with comorbidities — demographics more representative of standard obesity trial populations.
Management anticipates the higher-BMI cohort will demonstrate more pronounced improvements in body composition and weight reduction. Results from this phase will guide Wave’s strategic decisions across multiple therapeutic areas including obesity, MASH, type 2 diabetes, and cardiovascular conditions.
The day preceding the data release, Jefferies reaffirmed its Buy recommendation and $28 price target for WVE stock, emphasizing the company’s RNA editing technology and INHBE program as significant value drivers.
Jefferies analyst Roger Song highlighted potential competitive advantages of Wave’s platform: absence of off-target editing concerns, superior safety characteristics, and sustained therapeutic effects enabling convenient dosing intervals.
Additional Pipeline Developments
In a separate announcement, Wave reclaimed complete development rights to WVE-006 following its agreement with GSK. The company plans to showcase a poster presentation at ADA and anticipates releasing updates on 400mg multiple ascending dose and 600mg single ascending dose cohorts in May.
Mizuho elevated its price target for WVE to $27 from $22 earlier in 2025, maintaining an Outperform designation after Wave secured full ownership of WVE-006.
Wave recently disclosed Q4 and full-year 2025 financial results, acknowledging fiscal headwinds stemming from the conclusion of a significant partnership. While revenue exceeded analyst projections, earnings per share fell short of consensus estimates.
According to InvestingPro analysis, the company maintains a stronger cash position than its debt obligations.
Results from the RestorAATion-2 clinical trial evaluating WVE-006 are scheduled for presentation at the American Thoracic Society International Conference in 2026, featuring data from both the 400mg multidose and 600mg single-dose participant groups.
